RA
REGN icon

Riversedge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Riversedge Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
390
+31
+9% +$21.1K 0.03% 263
2026
Q1 		$277K Sell
359
-12
-3% -$9.19K 0.04% 156
2025
Q4 		$286K Buy
+371
New +$252K 0.05% 151

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Riversedge Advisors's REGN Position: Q2 2026 in Review

Riversedge Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 8.6% in Q2 2026, buying an estimated $21.1K and bringing the position to 390 shares worth $243K. The position accounts for 0.03% of the portfolio, ranked #263.

Riversedge Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $286K in Q4 2025. 454 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Riversedge Advisors held 390 shares of Regeneron Pharmaceuticals worth $243K as of Q2 2026.
  • Riversedge Advisors bought 31 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $21.1K.
  • Regeneron Pharmaceuticals made up 0.03% of Riversedge Advisors's portfolio in Q2 2026, its #263 holding.
  • Riversedge Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Riversedge Advisors's Regeneron Pharmaceuticals position peaked at $286K in Q4 2025.
  • 454 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Riversedge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.